147 related articles for article (PubMed ID: 17437612)
1. Plasma lipid peroxidation and progression of disability in multiple sclerosis.
Koch M; Mostert J; Arutjunyan AV; Stepanov M; Teelken A; Heersema D; De Keyser J
Eur J Neurol; 2007 May; 14(5):529-33. PubMed ID: 17437612
[TBL] [Abstract][Full Text] [Related]
2. Plasma S100beta and NSE levels and progression in multiple sclerosis.
Koch M; Mostert J; Heersema D; Teelken A; De Keyser J
J Neurol Sci; 2007 Jan; 252(2):154-8. PubMed ID: 17187827
[TBL] [Abstract][Full Text] [Related]
3. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
[TBL] [Abstract][Full Text] [Related]
4. Serum NSE level and disability progression in multiple sclerosis.
Koch MW; George S; Wall W; Wee Yong V; Metz LM
J Neurol Sci; 2015 Mar; 350(1-2):46-50. PubMed ID: 25686504
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
[TBL] [Abstract][Full Text] [Related]
6. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
Sayao AL; Devonshire V; Tremlett H
Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
[TBL] [Abstract][Full Text] [Related]
8. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
9. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
[TBL] [Abstract][Full Text] [Related]
10. An adverse lipid profile is associated with disability and progression in disability, in people with MS.
Tettey P; Simpson S; Taylor B; Blizzard L; Ponsonby AL; Dwyer T; Kostner K; van der Mei I
Mult Scler; 2014 Nov; 20(13):1737-44. PubMed ID: 24829292
[TBL] [Abstract][Full Text] [Related]
11. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
Rejdak K; Eikelenboom MJ; Petzold A; Thompson EJ; Stelmasiak Z; Lazeron RH; Barkhof F; Polman CH; Uitdehaag BM; Giovannoni G
Neurology; 2004 Oct; 63(8):1439-45. PubMed ID: 15505162
[TBL] [Abstract][Full Text] [Related]
12. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
[TBL] [Abstract][Full Text] [Related]
13. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Kallaur AP; Mezzaroba L; Lozovoy MAB; Sabino BS; Ferreira KPZ; Pereira WLCJ; Kaimen-Maciel DR; Dichi I; Reiche EMV
J Neurol Sci; 2017 Oct; 381():213-219. PubMed ID: 28991684
[TBL] [Abstract][Full Text] [Related]
15. Patient reported outcomes in benign multiple sclerosis.
Hviid LE; Healy BC; Rintell DJ; Chitnis T; Weiner HL; Glanz BI
Mult Scler; 2011 Jul; 17(7):876-84. PubMed ID: 21372114
[TBL] [Abstract][Full Text] [Related]
16. Genetic, Immune-Inflammatory, and Oxidative Stress Biomarkers as Predictors for Disability and Disease Progression in Multiple Sclerosis.
Kallaur AP; Reiche EMV; Oliveira SR; Simão ANC; Pereira WLCJ; Alfieri DF; Flauzino T; Proença CM; Lozovoy MAB; Kaimen-Maciel DR; Maes M
Mol Neurobiol; 2017 Jan; 54(1):31-44. PubMed ID: 26732588
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Kurtkze expanded disability status scale and the functional independence measure: measures of multiple sclerosis-related disability.
Rabadi MH; Vincent AS
Disabil Rehabil; 2013; 35(22):1877-84. PubMed ID: 23600712
[TBL] [Abstract][Full Text] [Related]
18. Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP).
Wynia K; van Wijlen AT; Middel B; Reijneveld SA; Meilof JF
Mult Scler; 2012 May; 18(5):654-61. PubMed ID: 21965423
[TBL] [Abstract][Full Text] [Related]
19. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
20. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH
Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
